Brant Point Investment Management LLC Has $5.19 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• Brant Point Investment Management LLC increased its holdings in IDEXX Laboratories by 23.5%, owning 12,348 shares valued at approximately $5.18 million as of its latest SEC filing.
• IDEXX reported an EPS of $3.63 for the last quarter, exceeding expectations, with a revenue of $1.11 billion, marking a year-over-year revenue increase of 10.6%.
• Several analysts have issued optimistic ratings on IDXX shares, with target prices ranging from $625 to $765, indicating a general consensus of "Moderate Buy".

Brant Point Investment Management LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 23.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,348 shares of the company's stock after buying an additional 2,348 shares during the quarter. IDEXX Laboratories makes up 0.6% of Brant Point Investment Management LLC's holdings, making the stock its 23rd biggest holding. Brant Point Investment Management LLC's holdings in IDEXX Laboratories were worth $5,186,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. MorganRosel Wealth Management LLC acquired a new stake in IDEXX Laboratories in the first quarter valued at about $26,000. Migdal Insurance & Financial Holdings Ltd. boosted its stake in IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after buying an additional 30 shares in the last quarter. Colonial Trust Co SC boosted its stake in IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after buying an additional 39 shares in the last quarter. Bank of Jackson Hole Trust boosted its stake in IDEXX Laboratories by 328.6% in the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock valued at $39,000 after buying an additional 69 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its stake in IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after buying an additional 81 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 0.0%

Shares of IDXX traded up $0.06 during mid-day trading on Monday, reaching $647.09. 304,946 shares of the company were exchanged, compared to its average volume of 691,259. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The stock has a market capitalization of $51.77 billion, a PE ratio of 53.88, a PEG ratio of 4.19 and a beta of 1.56. The business has a 50 day simple moving average of $582.04 and a two-hundred day simple moving average of $500.76.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the company earned $2.44 earnings per share. The firm's revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other news, CEO Jonathan Jay Mazelsky sold 29,260 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the completion of the transaction, the chief executive officer directly owned 83,311 shares in the company, valued at $52,650,885.78. This trade represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the sale, the director owned 262 shares of the company's stock, valued at approximately $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock valued at $34,293,468 over the last ninety days. Insiders own 0.98% of the company's stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several research analyst reports. Piper Sandler reaffirmed a "neutral" rating and issued a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Leerink Partners increased their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a research report on Monday, August 4th. Jefferies Financial Group began coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. Finally, JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research report on Monday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $649.44.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.